(VIANEWS) – The NASDAQ ended the session with Xenetic Biosciences (XBIO) jumping 13.81% to $0.53 on Tuesday while NASDAQ slid 0.27% to $11,334.27.

Xenetic Biosciences’s last close was $0.47, 62.4% under its 52-week high of $1.25.

Why is Xenetic Biosciences Stock Going Up?

Xenetic Biosciences (XBIO) is a biopharmaceutical company focused on advancing cell-based therapeutics targeting B-cell receptors. The company is also focused on developing the personalized Chimeric Antigen Receptor T (CART) platform. XCART targets patient-specific tumor neoantigens and has the potential to fuel a robust pipeline of therapeutic assets.

The Company’s products pipeline includes Polyxen, ErepoXen and XCART. These products are intended to treat patients with cancers that are locally advanced or metastatic to the pancreas. A product candidate, Epolong, met primary and secondary endpoints in its Phase 2 clinical trial.

As of yesterday, the Company’s current Earnings Per Share is -$0.51. Analysts predict that the Company will generate a loss of -$0.51 in 2025 and -$0.41 in 2023.

Xenetic Biosciences is engaged in the advancement of cell-based therapeutics for the treatment of high-value cancers. The Company’s DNase platform, for example, is designed to improve the outcomes of existing treatments. Xenetic Biosciences also partners with biotechnology companies, including PJSC Pharmsynthez, which is testing Epolong in anemia in chronic kidney disease.

XBIO has gained in value since its initial public offering in 2011. The stock has climbed 418.5% so far this year. During the same period, the average daily volume of the stock was 264,000 shares. This indicates that the stock is moving quite a bit during the day.

XBIO has received a Bullish sentiment from InvestorsObserver’s Stock Sentiment Indicator. This indicator considers recent trends in price and volume, as well as the company’s fundamentals. However, it does not reflect the overall health of the Company. Despite its positive sentiment, XBIO may be overbought and could correct down.

About Xenetic Biosciences

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Earnings per Share

Xenetic Biosciences’ trailing 12 months EPS is $-1.704.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was negative at -59.34%.


Today’s last reported volume for Xenetic Biosciences is 138778 which is 102.24% above its average volume of 68618.

Moving Average

Xenetic Biosciences’s worth is way above its 50-day moving average of $0.39 and way below its 200-day moving average of $0.66.

Growth Estimates Quarters

For the current quarter, the company expects a decline of 38.5% in growth and 46.2% for the following quarter.

Yearly Top and Bottom Value

Xenetic Biosciences’s stock is valued at $0.53 at 17:16 EST, way under its 52-week high of $1.25 and way higher than its 52-week low of $0.24.

More news about Xenetic Biosciences (XBIO).